LABELS · 2034440d-14ab-475e-affc-5261ac3683a6

Iclusig

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-08-14
Captured: 2026-09-09T23:37:42.544548+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: ARTERIAL OCCLUSIVE EVENTS, VENOUS THROMBOEMBOLIC EVENTS, HEART FAILURE, and HEPATOTOXICITY WARNING: ARTERIAL OCCLUSIVE EVENTS, VENOUS THROMBOEMBOLIC EVENTS, HEART FAILURE, and HEPATOTOXICITY See full prescribing information for complete boxed warning. Arterial occlusive events (AOEs), including fatalities, have occurred in ICLUSIG-treated patients. AOEs included fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures. Patients with and without cardiovascular risk factors, including patients age 50 years or younger, experienced these events. Monitor for evidence of AOEs. Interrupt or discontinue ICLUSIG based on severity. Consider benefit-risk to guide a decision to restart ICLUSIG. ( 2.2 , 5.1 ) Venous thromboembolic events (VTEs) have occurred in ICLUSIG-treated patients. Monitor for evidence of VTEs. Interrupt or discontinue ICLUSIG based on severity. ( 2.2 , 5.2 ) Heart failure, including fatalities, occurred in ICLUSIG-treated patients. Monitor for heart failure and manage patients as clinically indicated. Interrupt or discontinue ICLUSIG for new or worsening heart failure. ( 2.2 , 5.3 ) Hepatotoxicity, liver failure and death have occurred in ICLUSIG-treated patients. Monitor liver function tests. Interrupt or discontinue ICLUSIG based on severity. ( 2.2 , 5.4 ) Arterial Occlusive Events: Arterial occlusive events (AOEs), including fatalities, have occurred in ICLUSIG-treated patients. AOEs included fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures. Patients with and without cardiovascular risk factors, including patients age 50 years or younger, experienced these events. Monitor for evidence of AOEs. Interrupt or discontinue ICLUSIG based on severity. Consider benefit-risk to guide a decision to restart ICLUSIG [see Dosage and Administration (2.2) , Warnings and Precautions (5.1) ] . Venous Thromboembolic Events: Venous thromboembolic events (VTEs) have occurred in ICLUSIG-treated patients. Monitor for evidence of VTEs. Interrupt or discontinue ICLUSIG based on severity [see Dosage and Administration (2.2) , Warnings and Precautions (5.2) ] . Heart Failure: Heart failure, including fatalities, occurred in ICLUSIG-treated patients. Monitor for heart failure and manage patients as clinically indicated. Interrupt or discontinue ICLUSIG for new or worsening heart failure [see Dosage and Administration (2.2) , Warnings and Precautions (5.3) ] . Hepatotoxicity: Hepatotoxicity, liver failure and death have occurred in ICLUSIG-treated patients. Monitor liver function tests. Interrupt or discontinue ICLUSIG based on severity [see Dosage and Administration (2.2) , Warnings and Precautions (5.4) ] .

Indications and usage: exact source text

1 INDICATIONS AND USAGE ICLUSIG ® is indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL. Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors. Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated. T315I-positive CML (chronic phase, accelerated phase, or blast phase). ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL, in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 ) As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL. ( 1 ) Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors. ( 1 ) Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated. ( 1 ) T315I-positive CML (chronic phase, accelerated phase, or blast phase). ( 1 ) Limitations of Use : ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML. ( 5.7 ) Limitations of Use : ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML [see Warnings and Precautions (5.7) ] .

Full extracted label fields

application numbers

NDA203469

boxed warning exact

WARNING: ARTERIAL OCCLUSIVE EVENTS, VENOUS THROMBOEMBOLIC EVENTS, HEART FAILURE, and HEPATOTOXICITY WARNING: ARTERIAL OCCLUSIVE EVENTS, VENOUS THROMBOEMBOLIC EVENTS, HEART FAILURE, and HEPATOTOXICITY See full prescribing information for complete boxed warning. Arterial occlusive events (AOEs), including fatalities, have occurred in ICLUSIG-treated patients. AOEs included fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures. Patients with and without cardiovascular risk factors, including patients age 50 years or younger, experienced these events. Monitor for evidence of AOEs. Interrupt or discontinue ICLUSIG based on severity. Consider benefit-risk to guide a decision to restart ICLUSIG. ( 2.2 , 5.1 ) Venous thromboembolic events (VTEs) have occurred in ICLUSIG-treated patients. Monitor for evidence of VTEs. Interrupt or discontinue ICLUSIG based on severity. ( 2.2 , 5.2 ) Heart failure, including fatalities, occurred in ICLUSIG-treated patients. Monitor for heart failure and manage patients as clinically indicated. Interrupt or discontinue ICLUSIG for new or worsening heart failure. ( 2.2 , 5.3 ) Hepatotoxicity, liver failure and death have occurred in ICLUSIG-treated patients. Monitor liver function tests. Interrupt or discontinue ICLUSIG based on severity. ( 2.2 , 5.4 ) Arterial Occlusive Events: Arterial occlusive events (AOEs), including fatalities, have occurred in ICLUSIG-treated patients. AOEs included fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures. Patients with and without cardiovascular risk factors, including patients age 50 years or younger, experienced these events. Monitor for evidence of AOEs. Interrupt or discontinue ICLUSIG based on severity. Consider benefit-risk to guide a decision to restart ICLUSIG [see Dosage and Administration (2.2) , Warnings and Precautions (5.1) ] . Venous Thromboembolic Events: Venous thromboembolic events (VTEs) have occurred in ICLUSIG-treated patients. Monitor for evidence of VTEs. Interrupt or discontinue ICLUSIG based on severity [see Dosage and Administration (2.2) , Warnings and Precautions (5.2) ] . Heart Failure: Heart failure, including fatalities, occurred in ICLUSIG-treated patients. Monitor for heart failure and manage patients as clinically indicated. Interrupt or discontinue ICLUSIG for new or worsening heart failure [see Dosage and Administration (2.2) , Warnings and Precautions (5.3) ] . Hepatotoxicity: Hepatotoxicity, liver failure and death have occurred in ICLUSIG-treated patients. Monitor liver function tests. Interrupt or discontinue ICLUSIG based on severity [see Dosage and Administration (2.2) , Warnings and Precautions (5.4) ] .

brand names

Iclusig

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16d804b6-4957-43ee-b18c-3b36ec37c5ac

generic names

PONATINIB HYDROCHLORIDE

2034440d-14ab-475e-affc-5261ac3683a6

indications and usage exact

1 INDICATIONS AND USAGE ICLUSIG ® is indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL. Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors. Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated. T315I-positive CML (chronic phase, accelerated phase, or blast phase). ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL, in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 ) As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL. ( 1 ) Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors. ( 1 ) Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated. ( 1 ) T315I-positive CML (chronic phase, accelerated phase, or blast phase). ( 1 ) Limitations of Use : ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML. ( 5.7 ) Limitations of Use : ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML [see Warnings and Precautions (5.7) ] .

indications and usage tables exact

is original packager

true

manufacturer names

Takeda Pharmaceuticals America, Inc.

matched search terms

leukemia

package ndcs

63020-535-60
63020-535-30
63020-534-30
63020-533-30
63020-536-30

product ndcs

63020-533
63020-535
63020-534
63020-536

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Warnings and Precautions ( 5 ) 10/2025

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

1364352
1364358
1364360
1364362
1726637
1726639
2473040
2473042

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00100.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA203469

brand names

Iclusig

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 418
end exclusive: true
exact text: 1 INDICATIONS AND USAGE ICLUSIG ® is indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction [see Clinical Studies (14) ] . Continued approv
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 0

current approval status

not_reconciled

duplicate text group

dup-2ed294b1b20d8752ea80

extraction review status

automated_candidate_pending_source_review

generic names

PONATINIB HYDROCHLORIDE

ind-span-2390c615e3f97e330ee1

label id

2034440d-14ab-475e-affc-5261ac3683a6

positive predicate support span

end: 46
end exclusive: true
exact text: is indicated
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 34

qualifier mentions

context exact
TIONS AND USAGE ICLUSIG ® is indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic
kind
age
polarity
not_inferred
span
end
82
end exclusive
true
exact text
adult patients
label id
2034440d-14ab-475e-affc-5261ac3683a6
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start
68
context exact
te Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL in combination with chemotherapy.
kind
regimen
polarity
not_inferred
span
end
217
end exclusive
true
exact text
in combination with chemotherapy
label id
2034440d-14ab-475e-affc-5261ac3683a6
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start
185

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 218
end exclusive: true
exact text: 1 INDICATIONS AND USAGE ICLUSIG ® is indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL in combination with chemotherapy.
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%222034440d-14ab-475e-affc-5261ac3683a6%22

spl effective date

2026-08-14

spl set id

16d804b6-4957-43ee-b18c-3b36ec37c5ac

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · approval contingency

application numbers

NDA203469

brand names

Iclusig

classification reasons

approval_contingency_words

clinical review status

pending

content role

approval_contingency

context span

end: 601
end exclusive: true
exact text: SAGE ICLUSIG ® is indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 19

current approval status

not_reconciled

duplicate text group

dup-38c9884e6dd10d2f8bb4

extraction review status

automated_candidate_pending_source_review

generic names

PONATINIB HYDROCHLORIDE

ind-span-43bd8d1f5da1561e239e

label id

2034440d-14ab-475e-affc-5261ac3683a6

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 401
end exclusive: true
exact text: This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction [see Clinical Studies (14) ] .
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 219

source url

https://api.fda.gov/drug/label.json?search=id%3A%222034440d-14ab-475e-affc-5261ac3683a6%22

spl effective date

2026-08-14

spl set id

16d804b6-4957-43ee-b18c-3b36ec37c5ac

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 3 · approval contingency

application numbers

NDA203469

brand names

Iclusig

classification reasons

approval_contingency_words

clinical review status

pending

content role

approval_contingency

context span

end: 724
end exclusive: true
exact text: th chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL. Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance to at least
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 202

current approval status

not_reconciled

duplicate text group

dup-d065c8a542ebd7398368

extraction review status

automated_candidate_pending_source_review

generic names

PONATINIB HYDROCHLORIDE

ind-span-bafdb426fa8fcd941fef

label id

2034440d-14ab-475e-affc-5261ac3683a6

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 524
end exclusive: true
exact text: Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 402

source url

https://api.fda.gov/drug/label.json?search=id%3A%222034440d-14ab-475e-affc-5261ac3683a6%22

spl effective date

2026-08-14

spl set id

16d804b6-4957-43ee-b18c-3b36ec37c5ac

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 4 · positive indication candidate

application numbers

NDA203469

brand names

Iclusig

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 827
end exclusive: true
exact text: mplete remission (CR) at the end of induction [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL. Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors. Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase i
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 325

current approval status

not_reconciled

duplicate text group

dup-0abd7fc83627a6a497ee

extraction review status

automated_candidate_pending_source_review

generic names

PONATINIB HYDROCHLORIDE

ind-span-d7d8e98e47a645c5f03f

label id

2034440d-14ab-475e-affc-5261ac3683a6

positive predicate support span

end: 600
end exclusive: true
exact text: are indicated
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 587

qualifier mentions

context exact
As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.
kind
regimen
polarity
not_inferred
span
end
626
end exclusive
true
exact text
As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL
label id
2034440d-14ab-475e-affc-5261ac3683a6
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start
525

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 627
end exclusive: true
exact text: As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 525

source url

https://api.fda.gov/drug/label.json?search=id%3A%222034440d-14ab-475e-affc-5261ac3683a6%22

spl effective date

2026-08-14

spl set id

16d804b6-4957-43ee-b18c-3b36ec37c5ac

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 5 · unclassified context

application numbers

NDA203469

brand names

Iclusig

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 953
end exclusive: true
exact text: s indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL. Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors. Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated. T315I-positive CML (chronic phase, accelerated phase, or blast phase). ICLUSIG is a kinase inhibitor
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 428

current approval status

not_reconciled

duplicate text group

dup-37fa5a34c311062705ab

extraction review status

automated_candidate_pending_source_review

generic names

PONATINIB HYDROCHLORIDE

ind-span-4ee3e6d481d554ea68b3

label id

2034440d-14ab-475e-affc-5261ac3683a6

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 753
end exclusive: true
exact text: Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors.
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 628

source url

https://api.fda.gov/drug/label.json?search=id%3A%222034440d-14ab-475e-affc-5261ac3683a6%22

spl effective date

2026-08-14

spl set id

16d804b6-4957-43ee-b18c-3b36ec37c5ac

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · positive indication candidate

application numbers

NDA203469

brand names

Iclusig

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1051
end exclusive: true
exact text: whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL. Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors. Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated. T315I-positive CML (chronic phase, accelerated phase, or blast phase). ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphob
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 554

current approval status

not_reconciled

duplicate text group

dup-109408b93d0fd6ee6ee0

extraction review status

automated_candidate_pending_source_review

generic names

PONATINIB HYDROCHLORIDE

ind-span-a1b541b7960738d393c6

label id

2034440d-14ab-475e-affc-5261ac3683a6

positive predicate support span

end: 850
end exclusive: true
exact text: are indicated
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 837

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 851
end exclusive: true
exact text: Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated.
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 754

source url

https://api.fda.gov/drug/label.json?search=id%3A%222034440d-14ab-475e-affc-5261ac3683a6%22

spl effective date

2026-08-14

spl set id

16d804b6-4957-43ee-b18c-3b36ec37c5ac

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 7 · unclassified context

application numbers

NDA203469

brand names

Iclusig

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1122
end exclusive: true
exact text: (CML) Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors. Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated. T315I-positive CML (chronic phase, accelerated phase, or blast phase). ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL, in combination with
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 652

current approval status

not_reconciled

duplicate text group

dup-23c080fb0309bba57473

extraction review status

automated_candidate_pending_source_review

generic names

PONATINIB HYDROCHLORIDE

ind-span-2eaf095939b13de3a171

label id

2034440d-14ab-475e-affc-5261ac3683a6

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 922
end exclusive: true
exact text: T315I-positive CML (chronic phase, accelerated phase, or blast phase).
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 852

source url

https://api.fda.gov/drug/label.json?search=id%3A%222034440d-14ab-475e-affc-5261ac3683a6%22

spl effective date

2026-08-14

spl set id

16d804b6-4957-43ee-b18c-3b36ec37c5ac

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

NDA203469

brand names

Iclusig

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1335
end exclusive: true
exact text: t two prior kinase inhibitors. Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated. T315I-positive CML (chronic phase, accelerated phase, or blast phase). ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL, in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 723

current approval status

not_reconciled

duplicate text group

dup-4c1a559bda78fd19d89c

extraction review status

automated_candidate_pending_source_review

generic names

PONATINIB HYDROCHLORIDE

ind-span-89e48478f2d3d118698e

label id

2034440d-14ab-475e-affc-5261ac3683a6

positive predicate support span

end: 962
end exclusive: true
exact text: is a kinase inhibitor indicated
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 931

qualifier mentions

context exact
CLUSIG is a kinase inhibitor indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic
kind
age
polarity
not_inferred
span
end
998
end exclusive
true
exact text
adult patients
label id
2034440d-14ab-475e-affc-5261ac3683a6
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start
984
context exact
e Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL, in combination with chemotherapy.
kind
regimen
polarity
not_inferred
span
end
1134
end exclusive
true
exact text
in combination with chemotherapy
label id
2034440d-14ab-475e-affc-5261ac3683a6
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start
1102

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1135
end exclusive: true
exact text: ICLUSIG is a kinase inhibitor indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL, in combination with chemotherapy.
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 923

source url

https://api.fda.gov/drug/label.json?search=id%3A%222034440d-14ab-475e-affc-5261ac3683a6%22

spl effective date

2026-08-14

spl set id

16d804b6-4957-43ee-b18c-3b36ec37c5ac

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 9 · approval contingency

application numbers

NDA203469

brand names

Iclusig

classification reasons

approval_contingency_words

clinical review status

pending

content role

approval_contingency

context span

end: 1488
end exclusive: true
exact text: kinase inhibitor indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL, in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 ) As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indi
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 936

current approval status

not_reconciled

duplicate text group

dup-1ab7ea312e3941531214

extraction review status

automated_candidate_pending_source_review

generic names

PONATINIB HYDROCHLORIDE

ind-span-ae5408c63ddd8a92699f

label id

2034440d-14ab-475e-affc-5261ac3683a6

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1288
end exclusive: true
exact text: This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction.
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 1136

source url

https://api.fda.gov/drug/label.json?search=id%3A%222034440d-14ab-475e-affc-5261ac3683a6%22

spl effective date

2026-08-14

spl set id

16d804b6-4957-43ee-b18c-3b36ec37c5ac

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 10 · approval contingency

application numbers

NDA203469

brand names

Iclusig

classification reasons

approval_contingency_words

clinical review status

pending

content role

approval_contingency

context span

end: 1611
end exclusive: true
exact text: sed Ph+ ALL, in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 ) As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL. ( 1 ) Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 1089

current approval status

not_reconciled

duplicate text group

dup-d065c8a542ebd7398368

extraction review status

automated_candidate_pending_source_review

generic names

PONATINIB HYDROCHLORIDE

ind-span-ecea6eb657b69818063c

label id

2034440d-14ab-475e-affc-5261ac3683a6

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1411
end exclusive: true
exact text: Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 1289

source url

https://api.fda.gov/drug/label.json?search=id%3A%222034440d-14ab-475e-affc-5261ac3683a6%22

spl effective date

2026-08-14

spl set id

16d804b6-4957-43ee-b18c-3b36ec37c5ac

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 11 · positive indication candidate

application numbers

NDA203469

brand names

Iclusig

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1720
end exclusive: true
exact text: dual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 ) As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL. ( 1 ) Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors. ( 1 ) Accelerated phase (AP) or blast phase (BP) CML for whom no ot
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 1212

current approval status

not_reconciled

duplicate text group

dup-26c67f50fd186940e616

extraction review status

automated_candidate_pending_source_review

generic names

PONATINIB HYDROCHLORIDE

ind-span-5f5345feafa75d628c3f

label id

2034440d-14ab-475e-affc-5261ac3683a6

positive predicate support span

end: 1493
end exclusive: true
exact text: are indicated
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 1480

qualifier mentions

context exact
( 1 ) As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.
kind
regimen
polarity
not_inferred
span
end
1519
end exclusive
true
exact text
As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL
label id
2034440d-14ab-475e-affc-5261ac3683a6
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start
1418

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1520
end exclusive: true
exact text: ( 1 ) As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 1412

source url

https://api.fda.gov/drug/label.json?search=id%3A%222034440d-14ab-475e-affc-5261ac3683a6%22

spl effective date

2026-08-14

spl set id

16d804b6-4957-43ee-b18c-3b36ec37c5ac

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 12 · unclassified context

application numbers

NDA203469

brand names

Iclusig

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1852
end exclusive: true
exact text: cation may be contingent upon verification of clinical benefit in a confirmatory trial(s). ( 1 ) As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL. ( 1 ) Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors. ( 1 ) Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated. ( 1 ) T315I-positive CML (chronic phase, accelerated phase, or blast phase). ( 1 ) Limitations
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 1321

current approval status

not_reconciled

duplicate text group

dup-ff090d94be7e681b1b63

extraction review status

automated_candidate_pending_source_review

generic names

PONATINIB HYDROCHLORIDE

ind-span-eb3057368bf2b02fd0a5

label id

2034440d-14ab-475e-affc-5261ac3683a6

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1652
end exclusive: true
exact text: ( 1 ) Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors.
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 1521

source url

https://api.fda.gov/drug/label.json?search=id%3A%222034440d-14ab-475e-affc-5261ac3683a6%22

spl effective date

2026-08-14

spl set id

16d804b6-4957-43ee-b18c-3b36ec37c5ac

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 13 · positive indication candidate

application numbers

NDA203469

brand names

Iclusig

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1956
end exclusive: true
exact text: no other kinase inhibitors are indicated or T315I-positive Ph+ ALL. ( 1 ) Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors. ( 1 ) Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated. ( 1 ) T315I-positive CML (chronic phase, accelerated phase, or blast phase). ( 1 ) Limitations of Use : ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagno
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 1453

current approval status

not_reconciled

duplicate text group

dup-aa7e0acdb83b037ac34f

extraction review status

automated_candidate_pending_source_review

generic names

PONATINIB HYDROCHLORIDE

ind-span-e45b8c904832a66c3535

label id

2034440d-14ab-475e-affc-5261ac3683a6

positive predicate support span

end: 1755
end exclusive: true
exact text: are indicated
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 1742

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1756
end exclusive: true
exact text: ( 1 ) Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated.
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 1653

source url

https://api.fda.gov/drug/label.json?search=id%3A%222034440d-14ab-475e-affc-5261ac3683a6%22

spl effective date

2026-08-14

spl set id

16d804b6-4957-43ee-b18c-3b36ec37c5ac

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 14 · unclassified context

application numbers

NDA203469

brand names

Iclusig

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 2033
end exclusive: true
exact text: Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors. ( 1 ) Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated. ( 1 ) T315I-positive CML (chronic phase, accelerated phase, or blast phase). ( 1 ) Limitations of Use : ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML. ( 5.7 ) Limitations of Use : ICLUSIG is not indicated and is not
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 1557

current approval status

not_reconciled

duplicate text group

dup-6b0fb3914f895ab73b0e

extraction review status

automated_candidate_pending_source_review

generic names

PONATINIB HYDROCHLORIDE

ind-span-daaaa4cae70479c42d64

label id

2034440d-14ab-475e-affc-5261ac3683a6

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1833
end exclusive: true
exact text: ( 1 ) T315I-positive CML (chronic phase, accelerated phase, or blast phase).
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 1757

source url

https://api.fda.gov/drug/label.json?search=id%3A%222034440d-14ab-475e-affc-5261ac3683a6%22

spl effective date

2026-08-14

spl set id

16d804b6-4957-43ee-b18c-3b36ec37c5ac

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 15 · limitation of use

application numbers

NDA203469

brand names

Iclusig

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 2142
end exclusive: true
exact text: kinase inhibitors. ( 1 ) Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated. ( 1 ) T315I-positive CML (chronic phase, accelerated phase, or blast phase). ( 1 ) Limitations of Use : ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML. ( 5.7 ) Limitations of Use : ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML [see Warnings and Precautions (5.7) ] .
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 1634

current approval status

not_reconciled

duplicate text group

dup-c7a8c958c5916f4cb29e

extraction review status

automated_candidate_pending_source_review

generic names

PONATINIB HYDROCHLORIDE

ind-span-7180f87bcc13f5f82d70

label id

2034440d-14ab-475e-affc-5261ac3683a6

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1967
end exclusive: true
exact text: ( 1 ) Limitations of Use : ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 1834

source url

https://api.fda.gov/drug/label.json?search=id%3A%222034440d-14ab-475e-affc-5261ac3683a6%22

spl effective date

2026-08-14

spl set id

16d804b6-4957-43ee-b18c-3b36ec37c5ac

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 16 · limitation of use

application numbers

NDA203469

brand names

Iclusig

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 2142
end exclusive: true
exact text: -positive CML (chronic phase, accelerated phase, or blast phase). ( 1 ) Limitations of Use : ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML. ( 5.7 ) Limitations of Use : ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML [see Warnings and Precautions (5.7) ] .
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 1768

current approval status

not_reconciled

duplicate text group

dup-05d90e3b65e9dab03ca1

extraction review status

automated_candidate_pending_source_review

generic names

PONATINIB HYDROCHLORIDE

ind-span-9aab513cba4aefc33f91

label id

2034440d-14ab-475e-affc-5261ac3683a6

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 2142
end exclusive: true
exact text: ( 5.7 ) Limitations of Use : ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML [see Warnings and Precautions (5.7) ] .
label id: 2034440d-14ab-475e-affc-5261ac3683a6
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: fb329689c197c96c8a9b0e114498e315832271d6f584ecbfcfaf8b182281d8b3
start: 1968

source url

https://api.fda.gov/drug/label.json?search=id%3A%222034440d-14ab-475e-affc-5261ac3683a6%22

spl effective date

2026-08-14

spl set id

16d804b6-4957-43ee-b18c-3b36ec37c5ac

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Preserved source evidence · Not medical advice